Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Adrian C Jaramillo, Andries M Bergman, Elizabeth M Comijn, Gerrit Jansen, Gertjan J L Kaspers, Jacqueline Cloos & Godefridus J Peters. (2020) Effect of dexamethasone on the antileukemic effect of cytarabine: role of deoxycytidine kinase. Nucleosides, Nucleotides & Nucleic Acids 39:10-12, pages 1346-1346.
Read now
Read now
Niamh Keane, Ciara Freeman, Ronan Swords & Francis J Giles. (2013) Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Review of Hematology 6:1, pages 9-24.
Read now
Read now
David J. Adams, Marit L. Sandvold, Finn Myhren, Tove F. Jacobsen, Frank Giles & David A. Rizzieri. (2008) Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leukemia & Lymphoma 49:4, pages 786-797.
Read now
Read now
Nina Anensen, Anne M Øyan, Sjur Huseby, Karl-Henning Kalland, Øystein Bruserud & Bjørn T Gjertsen. (2007) Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy 7:5, pages 741-751.
Read now
Read now
Articles from other publishers (49)
Zhenyu Nie, Mei Chen, Yuanhui Gao, Denggao Huang, Hui Cao, Yanling Peng, Na Guo, Fei Wang & Shufang Zhang. (2022) Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. Frontiers in Pharmacology 13.
Crossref
Crossref
Bwalya Angel Witika, Madan Sai Poka, Patrick Hulisani Demana, Scott Kaba Matafwali, Siyabonga Melamane, Sandile Maswazi Malungelo Khamanga & Pedzisai Anotida Makoni. (2022) Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date. Pharmaceutics 14:4, pages 836.
Crossref
Crossref
Ashley D. Hadjis, Natalia S. Nunes, Shanzay M. Khan, Rochelle E. Fletcher, Alessandra de Paula Pohl, David J. Venzon, Michael A. Eckhaus & Christopher G. Kanakry. (2022) Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology 13.
Crossref
Crossref
Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, Anna Aviñó, Yáiza Núñez, Annabel García-León, Laura Sánchez-García, Naroa Serna, Alberto Gallardo, Lorena Alba-Castellón, Patricia Álamo, Jorge Sierra, Lídia Cedó, Ramon Eritja, Antonio Villaverde, Esther Vázquez, Isolda Casanova & Ramon Mangues. (2022) A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. Biomaterials 280, pages 121258.
Crossref
Crossref
Weimin Zuo & Hang Fai Kwok. (2021) Development of Marine-Derived Compounds for Cancer Therapy. Marine Drugs 19:6, pages 342.
Crossref
Crossref
Parastoo Modarres, Farzaneh Mohamadi Farsani, Amir Abas Nekouie & Sadeq Vallian. (2021) Meta-analysis of gene signatures and key pathways indicates suppression of JNK pathway as a regulator of chemo-resistance in AML. Scientific Reports 11:1.
Crossref
Crossref
Guadalupe Rosario Fajardo-Orduña, Edgar Ledesma-Martínez, Itzen Aguiñiga-Sánchez, María de Lourdes Mora-García, Benny Weiss-Steider & Edelmiro Santiago-Osorio. (2021) Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review. International Journal of Molecular Sciences 22:9, pages 4955.
Crossref
Crossref
Biao Wu, Zhengwei Jenny Mao, Zhi Wang, Pin Wu, Hongyu Huang, Wenjun Zhao, Lei Zhang, Zhou Zhang, Hongchao Yin, Robert Peter Gale & Bin Yin. (2021) Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine. Acta Haematologica 144:5, pages 534-541.
Crossref
Crossref
Chadi Abbara, Guillaume Drevin, Séverine Férec, Sarah Ghamrawi, Simon Souchet, Jean-Baptiste Robin, Aline Schmidt, Mathilde Hunault-Berger, Philippe Guardiola & Marie Briet. (2020) Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples. Cancer Chemotherapy and Pharmacology 86:5, pages 687-691.
Crossref
Crossref
Christine L. Phillips, Adam Lane, Robert B. Gerbing, Todd A. Alonzo, Alyss Wilkey, Gretchen Radloff, Beverly Lange, Eric R. Gamazon, M. Eileen Dolan & Stella M. Davies. (2020) Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group. Clinical Cancer Research 26:12, pages 2891-2897.
Crossref
Crossref
Mukta Agrawal, Swarnlata Saraf, Shailendra Saraf, Sunil Kumar Dubey, Anu Puri, Ravish J. Patel, Ajazuddin, V. Ravichandiran, Upadhyayula Suryanarayana Murty & Amit Alexander. (2020) Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. Journal of Controlled Release 321, pages 372-415.
Crossref
Crossref
R. F. Schlenk, D. Weber, W. Herr, G. Wulf, H. R. Salih, H. G. Derigs, A. Kuendgen, M. Ringhoffer, B. Hertenstein, U. M. Martens, M. Grießhammer, H. Bernhard, J. Krauter, M. Girschikofsky, D. Wolf, E. Lange, J. Westermann, E. Koller, S. Kremers, M. Wattad, M. Heuser, F. Thol, G. Göhring, D. Haase, V. Teleanu, V. Gaidzik, A. Benner, K. Döhner, A. Ganser, P. Paschka & H. Döhner. (2019) Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. Leukemia 33:8, pages 1923-1933.
Crossref
Crossref
Ya-Chen Ko, Chung-Yi Hu, Zheng-Hau Liu, Hwei-Fang Tien, Da-Liang Ou, Hsiung-Fei Chien & Liang-In Lin. (2019) Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib. International Journal of Molecular Sciences 20:5, pages 1230.
Crossref
Crossref
Jonathan A. Webster, Raoul Tibes, Larry Morris, Amanda L. Blackford, Mark Litzow, Mrinal Patnaik, Gary L. Rosner, Ivana Gojo, Robert Kinders, Lihua Wang, L. Austin Doyle, Catherine J. Huntoon, Larry M. Karnitz, Scott H. Kaufmann, Judith E. Karp & B. Douglas Smith. (2017) Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research 61, pages 108-116.
Crossref
Crossref
Giovanni Li VoltiDaniele TibulloLuca VanellaCesarina GiallongoFrancesco Di RaimondoStefano ForteMichelino Di RosaSalvatore Santo SignorelliIgnazio Barbagallo. (2017) The Heme Oxygenase System in Hematological Malignancies. Antioxidants & Redox Signaling 27:6, pages 363-377.
Crossref
Crossref
D Malani, A Murumägi, B Yadav, M Kontro, S Eldfors, A Kumar, R Karjalainen, M M Majumder, P Ojamies, T Pemovska, K Wennerberg, C Heckman, K Porkka, M Wolf, T Aittokallio & O Kallioniemi. (2016) Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia 31:5, pages 1187-1195.
Crossref
Crossref
Zheng Li, Jian-Ru Guo, Qian-Qian Chen, Cai-Yun Wang, Wei-Jia Zhang, Mei-Cun Yao & Wei Zhang. (2017) Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells. Molecules 22:3, pages 499.
Crossref
Crossref
Mohammad HoushmandMasoud SoleimaniAmir AtashiGiuseppe SaglioMohammad AbdollahiMahin Nikougoftar Zarif. (2017) Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening. Tissue Engineering Part C: Methods 23:2, pages 72-85.
Crossref
Crossref
Hongmei Ruan, Songbo Qiu, Brian C. Beard & Margaret E. Black. (2016) Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells. Protein Engineering Design and Selection, pages gzw012.
Crossref
Crossref
C Müller-Tidow, P Tschanter, C Röllig, C Thiede, A Koschmieder, M Stelljes, S Koschmieder, M Dugas, J Gerss, T Butterfaß-Bahloul, R Wagner, M Eveslage, U Thiem, S W Krause, U Kaiser, V Kunzmann, B Steffen, R Noppeney, W Herr, C D Baldus, N Schmitz, K Götze, A Reichle, M Kaufmann, A Neubauer, K Schäfer-Eckart, M Hänel, R Peceny, N Frickhofen, M Kiehl, A Giagounidis, M Görner, R Repp, H Link, A Kiani, R Naumann, T H Brümmendorf, H Serve, G Ehninger, W E Berdel & U Krug. (2015) Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia. Leukemia 30:3, pages 555-561.
Crossref
Crossref
Ofir Wolach, Gilad Itchaki, Michal Bar-Natan, Moshe Yeshurun, Ron Ram, Corina Herscovici, Ofer Shpilberg, Dan Douer, Martin S. Tallman & Pia Raanani. (2016) High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. Hematological Oncology 34:1, pages 28-35.
Crossref
Crossref
Neha S. Bhise, Lata Chauhan, Miyoung Shin, Xueyuan Cao, Stanley Pounds, Vishal Lamba & Jatinder K. Lamba. (2016) MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients. Frontiers in Pharmacology 6.
Crossref
Crossref
Andrea Viale & Giulio F. Draetta. 2016. Metabolism in Cancer. Metabolism in Cancer
135
156
.
Zsuzsanna Marton, Rémi Guillon, Isabelle Krimm, Preeti, Rahila Rahimova, David Egron, Lars P. Jordheim, Nushin Aghajari, Charles Dumontet, Christian Périgaud, Corinne Lionne, Suzanne Peyrottes & Laurent Chaloin. (2015) Identification of Noncompetitive Inhibitors of Cytosolic 5′-Nucleotidase II Using a Fragment-Based Approach. Journal of Medicinal Chemistry 58:24, pages 9680-9696.
Crossref
Crossref
Dae Sik Kim, Ka-Won Kang, Se Ryeon Lee, Yong Park, Hwa Jung Sung, Seok Jin Kim, Chul Won Choi & Byung Soo Kim. (2015) Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines. Annals of Hematology 94:9, pages 1485-1492.
Crossref
Crossref
Krisztina Mita Gabor, Geza Schermann, Orsolya Lautner-Csorba, Ferenc Rarosi, Daniel J. Erdelyi, Emoke Endreffy, Krisztina Berek, Katalin Bartyik, Csaba Bereczki, Csaba Szalai & Agnes F. Semsei. (2015) Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer 62:4, pages 622-628.
Crossref
Crossref
Aurora Medina-Sanson, Arturo Ram?rez-Pacheco, Silvia Selene Moreno-Guerrero, Elisa Mar?a Dorantes-Acosta, Metzeri S?nchez-Preza & Alfonso Reyes-L?pez. (2015) Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia. BioMed Research International 2015, pages 1-10.
Crossref
Crossref
Mihajlo Bosnjak, Biljana Ristic, Katarina Arsikin, Aleksandar Mircic, Violeta Suzin-Zivkovic, Vladimir Perovic, Andrija Bogdanovic, Verica Paunovic, Ivanka Markovic, Vladimir Bumbasirevic, Vladimir Trajkovic & Ljubica Harhaji-Trajkovic. (2014) Inhibition of mTOR-Dependent Autophagy Sensitizes Leukemic Cells to Cytarabine-Induced Apoptotic Death. PLoS ONE 9:4, pages e94374.
Crossref
Crossref
Xueyuan Cao, Amit K Mitra, Stanley Pounds, Kristine R Crews, Varsha Gandhi, William Plunkett, M Eileen Dolan, Christine Hartford, Susana Raimondi, Dario Campana, James Downing, Jeffrey E Rubnitz, Raul C Ribeiro & Jatinder K Lamba. (2013)
RRM1
and
RRM2
pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients
. Pharmacogenomics 14:12, pages 1449-1466.
Crossref
Crossref
Mikkel Krogh-Madsen, Steen Hansen Honor?Morten Krogh Jensen, Ove Juul Nielsen, Hannah S?ndergaard Jensen & Per Hartvig Honor?. (2013) Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia. European Journal of Hospital Pharmacy 20:3, pages 185-188.
Crossref
Crossref
Dong-Oh Moon, Yukihiro Asami, Mun-Ock Kim, Jae-Hyuk Jang, Bo Yeon Kim, Jong Seog Ahn, Gi-Young Kim & Sung Gyu Yun. (2013) Xestospongin C induces monocytic differentiation of HL60 cells through activation of the ERK pathway. Food and Chemical Toxicology 55, pages 505-512.
Crossref
Crossref
Utz Krug, Anja Koschmieder, Daniela Schwammbach, Joachim Gerss, Nicola Tidow, Bj?rn Steffen, Gesine Bug, Christian H. Brandts, Markus Schaich, Christoph R?llig, Christian Thiede, Richard Noppeney, Matthias Stelljes, Thomas B?chner, Steffen Koschmieder, Ulrich D?hrsen, Hubert Serve, Gerhard Ehninger, Wolfgang E. Berdel & Carsten M?ller-Tidow. (2012) Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia ? A Randomised SAL Pilot Study. PLoS ONE 7:12, pages e52695.
Crossref
Crossref
Mikkel Krogh-Madsen, Brendan Bender, Morten Krogh Jensen, Ove Juul Nielsen, Lena E. Friberg & Per Hartvig Honoré. (2012) Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 69:5, pages 1155-1163.
Crossref
Crossref
William R. Waud, Karen S. Gilbert & John A. SecristIIIIII. (2010) Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias. Cancer Chemotherapy and Pharmacology 68:2, pages 399-403.
Crossref
Crossref
Jatinder K LambaKristine R Crews, Stanley B Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Bassem I Razzouk, Vishal Lamba, Sharyn D Baker, Susana C Raimondi, Dario Campana, Ching-Hon Pui, James R Downing, Jeffrey E Rubnitz & Raul C Ribeiro. (2011) Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12:3, pages 327-339.
Crossref
Crossref
Ping Chen, Josephine Aimiuwu, Zhiliang Xie, Xiaohui Wei, Shujun Liu, Rebecca Klisovic, Guido Marcucci & Kenneth K. Chan. (2010) Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells. The AAPS Journal 13:1, pages 131-140.
Crossref
Crossref
June-Won Cheong, Haeng-Im Jung, Ju In Eom, Soo Jung Kim, Hoi-Kyung Jeung & Yoo Hong Min. (2010) Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe. Cancer Letters 297:2, pages 171-181.
Crossref
Crossref
Heiko Singer, Christian Kellner, Harald Lanig, Michael Aigner, Bernhard Stockmeyer, Fuat Oduncu, Michael Schwemmlein, Christoph Stein, Kristin Mentz, Andreas Mackensen & Georg H. Fey. (2010) Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16. Journal of Immunotherapy 33:6, pages 599-608.
Crossref
Crossref
Pallavi Lagisetty, Prachi Vilekar & Vibhudutta Awasthi. (2009) Synthesis of radiolabeled cytarabine conjugates. Bioorganic & Medicinal Chemistry Letters 19:16, pages 4764-4767.
Crossref
Crossref
Christine M. Hartford, Shiwei Duan, Shannon M. Delaney, Shuangli Mi, Emily O. Kistner, Jatinder K. Lamba, R. Stephanie Huang & M. Eileen Dolan. (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113:10, pages 2145-2153.
Crossref
Crossref
Sarah A. Holstein & Raymond J. Hohl. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
83
90
.
Henrick Horita, Arthur E. Frankel & Andrew Thorburn. (2008) Acute Myeloid Leukemia-Targeted Toxin Activates Both Apoptotic and Necroptotic Death Mechanisms. PLoS ONE 3:12, pages e3909.
Crossref
Crossref
Maria M. Ho, Donna E. Hogge & Victor Ling. (2008) MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Experimental Hematology 36:4, pages 433-442.
Crossref
Crossref
Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Erin G. Schuetz, Jessica Gresham, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz & Raul Ribeiro. (2007) Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants. Journal of Pharmacology and Experimental Therapeutics 323:3, pages 935-945.
Crossref
Crossref
Bin Yin, Scott C. Kogan, Ross A. Dickins, Scott W. Lowe & David A. Largaespada. (2006) Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Experimental Hematology 34:5, pages 631-641.
Crossref
Crossref
Je-Hwan Lee, Seong-Jun Choi, Jung-Hee Lee, Young-Shin Lee, Miee Seol, Seong-Gil Ryu, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Jung-Shin Lee, Woo-Kun Kim & Kyoo-Hyung Lee. (2006) Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. Leukemia Research 30:2, pages 204-210.
Crossref
Crossref
B Yin, K Morgan, D E Hasz, Z Mao & D A Largaespada. (2005) Nf1 gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 20:1, pages 151-154.
Crossref
Crossref
Ismael Samudio, Marina Konopleva, Stephen Safe, Teresa McQueen & Michael Andreeff. (2005) Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Molecular Cancer Therapeutics 4:12, pages 1982-1992.
Crossref
Crossref
Dzung H. Nguyen, Pam Tangvoranuntakul & Ajit Varki. (2005) Effects of Natural Human Antibodies against a Nonhuman Sialic Acid That Metabolically Incorporates into Activated and Malignant Immune Cells. The Journal of Immunology 175:1, pages 228-236.
Crossref
Crossref